Clinical Trial Update: Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating arsenic trioxide (Trisenox) in patients with myelodysplastic syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Trisenox (arsenic trioxide)

Snippet

Sponsor: Oncology Specialties, Alabama | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: TERMINATED